Evolus Inc (EOLS)

Feb 20, 2025

Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Feb 20, 2025

Feb 20, 2025

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace

Feb 20, 2025

Feb 20, 2025

Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan

Feb 20, 2025

Feb 19, 2025

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace

Feb 19, 2025

Feb 18, 2025

Evolus Sets Date for Key 2024 Financial Results: What the Beauty Industry is Watching - StockTitan

Feb 18, 2025

Feb 18, 2025

Evolus (NASDAQ:EOLS) Receives Buy Rating from HC Wainwright - MarketBeat

Feb 18, 2025

Feb 17, 2025

Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Feb 17, 2025

Feb 17, 2025

Evolus (NASDAQ:EOLS) Trading 15.3% HigherTime to Buy? - MarketBeat

Feb 17, 2025

Feb 17, 2025

Evolus's SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Australia

Feb 17, 2025

Feb 17, 2025

Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com

Feb 17, 2025

Feb 17, 2025

Evolus's SWOT analysis: FDA nod for filler boosts stock outlook - MSN

Feb 17, 2025

Feb 17, 2025

Evolus’s SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Nigeria

Feb 17, 2025

Feb 16, 2025

(EOLS) Technical Data - Stock Traders Daily

Feb 16, 2025

Feb 14, 2025

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? - MSN

Feb 14, 2025

Feb 14, 2025

FDA approves two hyaluronic acid fillers for nasolabial folds - Healio

Feb 14, 2025

Feb 14, 2025

FDA Approves Two New Hyaluronic Acid Dermal Fillers - Medical Dialogues

Feb 14, 2025

Feb 14, 2025

Breaking Down Evolus: 4 Analysts Share Their Views - Benzinga

Feb 14, 2025

Feb 14, 2025

A great week that adds to Evolus, Inc.'s (NASDAQ:EOLS) one-year returns, institutional investors who own 70% must be happy - Simply Wall St

Feb 14, 2025

Feb 13, 2025

Sector Update: Health Care -February 13, 2025 at 03:38 pm EST - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels -February 13, 2025 at 02:11 pm EST - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

US FDA approves Evolus' anti-wrinkle gels - TradingView

Feb 13, 2025

Feb 13, 2025

US FDA approves Evolus' anti-wrinkle gels -February 13, 2025 at 02:02 pm EST - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

Evolus, Inc. Announces FDA Approval of Evolysse?? Form and Evolysse?? Smooth Injectable Hyaluronic Acid Gels - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

Game-Changing FDA Approval: Evolus Unveils Next-Gen Dermal Fillers That Outperform Restylane - StockTitan

Feb 13, 2025

Feb 10, 2025

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing - Yahoo Finance

Feb 10, 2025

Feb 09, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace

Feb 09, 2025

Feb 08, 2025

Evolus (NASDAQ:EOLS) Trading Down 6.5%Here's Why - MarketBeat

Feb 08, 2025

Feb 08, 2025

Unlocking Beauty: Evolus Sparks Excitement with New Stock Awards for Employees! - Mi Valle

Feb 08, 2025

Feb 08, 2025

Acelyrin (NASDAQ:SLRN) versus Evolus (NASDAQ:EOLS) Financial Contrast - Defense World

Feb 08, 2025

Feb 08, 2025

Unlocking Beauty: Evolus Rewards New Talent with Stock Options and RSUs - Trabajo News

Feb 08, 2025

Feb 07, 2025

Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push - StockTitan

Feb 07, 2025

Feb 05, 2025

BlackRock, Inc. Expands Stake in Evolus Inc with Strategic Acqui - GuruFocus.com

Feb 05, 2025

Feb 05, 2025

How the (EOLS) price action is used to our Advantage - Stock Traders Daily

Feb 05, 2025

Jan 31, 2025

Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World

Jan 31, 2025

Jan 28, 2025

Barclays Issues Positive Forecast for Evolus (NASDAQ:EOLS) Stock Price - Defense World

Jan 28, 2025

Jan 27, 2025

Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News

Jan 27, 2025

Jan 27, 2025

Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat

Jan 27, 2025

Jan 25, 2025

Stifel maintains Buy on Evolus, price target steady at $25 - MSN

Jan 25, 2025

Jan 25, 2025

HC Wainwright Issues Optimistic Outlook for Evolus Earnings - Defense World

Jan 25, 2025

Jan 24, 2025

Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal

Jan 24, 2025

Jan 24, 2025

FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat

Jan 24, 2025

Jan 24, 2025

HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat

Jan 24, 2025

Jan 23, 2025

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN

Jan 23, 2025

Jan 23, 2025

Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St

Jan 23, 2025

Jan 22, 2025

HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat

Jan 22, 2025

Jan 22, 2025

4 Analysts Have This To Say About Evolus - Benzinga

Jan 22, 2025

Jan 22, 2025

Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia

Jan 22, 2025